S
Sojournix
Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders
About Sojournix
Sojournix is a pharmaceutical company dedicated to developing innovative non-hormonal therapies for menopausal vasomotor symptoms (VMS), such as hot flashes. The company operates in the healthcare and pharmaceutical market, targeting women experiencing moderate to severe VMS during and after menopause. Sojournix's core product, SJX 653, is a novel, potent, and selective neurokinin 3 (NK3) antagonist currently in clinical development. This once-daily treatment aims to provide a safe and effective alternative to hormone therapy, which carries potential safety risks, and other non-hormonal therapies that have limited efficacy.
Sojournix's business model revolves around the research, development, and commercialization of its proprietary therapies. The company generates revenue through the successful development and eventual sale or licensing of its pharmaceutical products. By addressing a significant unmet medical need, Sojournix aims to capture a substantial share of the VMS treatment market.
Source: Dealroom company dataAt a glance
- Status
- Closed
- Founded
- 2016
- Headquarters
- Waltham, United States
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Femtech, Sustainable Development Goals, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2019 | $44M | $176M | Venrock · Boxer Capital · RA Capital Management · Frazier Healthcare Partners | ↗ |
| SERIES BOther financing | Dec 2017 | $19M | $76M | Undisclosed | — |
Growth signals
Latest recorded traffic for Sojournix is 230 monthly website visits, down 45.2% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later5 investors entered at this stage
RA Capital Management
Venrock
Boxer Capital
Frazier Healthcare Partners
Janus Henderson Investors
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sojournix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sojournix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.